|
|
Article: Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA; Agency strengthens 'black box' warning on medicines such as Enbrel, Remicade.
- Article from:
- Consumer Health News (English)
- Article date:
- August 4, 2009
CopyrightCOPYRIGHT 2009 HealthDay. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Steven Reinberg, HealthDay Reporter
TUESDAY, Aug. 4 (HealthDay News) -- Drugs widely used to fight rheumatoid arthritis, Crohn's disease and other inflammatory disorders must now carry an updated "black box" warning label cautioning patients and doctors that the medicines may boost cancer risk in children and adolescents, the U.S. Food and Drug Administration announced Tuesday.
The drugs, called tumor necrosis factor (TNF) blockers, work by interrupting a protein that causes inflammation and damage to bones, cartilage and other tissue. They include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and ...